Choose Language
Select a language for news translation.
Written by Neil Patel for The Motley Fool -> Coca-Cola has increased its dividend payout in a jaw-dropping 63 straight years. This is a high-quality business…
Written by Selena Maranjian for The Motley Fool -> Pfizer has a rich pipeline of drugs in development, at least some of which are likely to sell well. UPS ha…
As I do now and then, I'm here to recommend an exchange-traded fund (ETF) for your consideration. (Remember that ETFs are funds that trade like stocks.) Specif…
Written by Selena Maranjian for The Motley Fool -> This ETF's dividend yield was recently a solid 3.25%, about three times that of the S&P 500. Its growth ra…
Written by Katie Brockman for The Motley Fool -> IVV offers a significantly lower expense ratio and higher trailing-12-month dividend yield than QQQ. QQQ has…
Written by James Brumley for The Motley Fool -> Pfizer’s net income is under pressure, and likely will be for the foreseeable future. Although its replenishe…
Written by Reuben Gregg Brewer for The Motley Fool -> Pfizer is a highly respected pharmaceutical company. The drug maker is dealing with a mismatch between …
The S&P 500 index (SNPINDEX: ^GSPC) has a tiny yield of 1.1%. The average pharmaceutical company's yield is 1.7%. Those comparison points make Pfizer 's (NYSE:…
Written by Matt Frankel for The Motley Fool -> Ryman Hospitality Properties has dramatically outperformed the overall real estate sector in recent months. It…
Written by Micah Zimmerman for The Motley Fool -> McCormick combines a century-long dividend record with transformative merger-driven growth potential. Cloro…
Written by Neil Patel for The Motley Fool -> For any retailer, there's one data point that provides a clear look at how the business is performing in any give…
